Navigation Links
Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology
Date:10/4/2010

THOUSAND OAKS, Calif., Oct. 4 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that results from the PRIME '203' and '181' pivotal Phase 3 trials evaluating Vectibix® (panitumumab) in combination with chemotherapy (FOLFOX or FOLFIRI) as a first and second-line treatment for metastatic colorectal cancer (mCRC), respectively, were published online in the Journal of Clinical Oncology.

"Both studies demonstrated that Vectibix administered with chemotherapy significantly improved progression-free survival in patients with wild-type KRAS mCRC," said Marc Peeters, M.D., Ph.D., Professor of Oncology, Antwerp University Hospital and '181' trial lead investigator and study author. "The adverse event profiles in both trials were as expected for an anti-EGFR antibody treatment used in combination with these types of chemotherapy regimens. Additionally, these data reinforce that KRAS status should be known when choosing treatment strategies."

PRIME '203' Results in First-Line mCRC Demonstrate Vectibix Combined with Chemotherapy (FOLFOX) Helped Patients with Wild-type KRAS mCRC Live Longer Without their Disease Worsening (Progression-Free Survival or PFS)

  • The addition of Vectibix to FOLFOX (an oxaliplatin-based chemotherapy) significantly improved PFS (median 9.6 months for Vectibix plus FOLFOX versus 8.0 months for patients treated with FOLFOX alone, hazard ratio 0.80; 95 percent CI: 0.66-0.97; p=0.02) in the first-line treatment of patients with wild-type KRAS mCRC.  
  • Although numerically greater (23.9 months versus 19.7 months, hazard ratio 0.83; 95 percent CI: 0.67-1.02), the improvement in overall survival (OS) (secondary endpoint) in the Vectibix arm did not achieve statistical significance (p=0.072) in the same patient population.
  • Importantly, in patients with tumors harb
    '/>"/>

  • SOURCE Amgen
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
    2. Positive SPA Reply From the FDA for TopoTargets Pivotal Trial With Belinostat in PTCL
    3. Fifth DuraHeart(TM) U.S. Implant Marks Important Milestone in U.S. Pivotal Trial
    4. Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial
    5. Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH
    6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point
    7. BioSyntech to conclude enrolment for pivotal BST-CarGel(R) trial in February 2009
    8. BioSyntech Achieves Enrolment Goal for Pivotal Trial of BST-CarGel(R), its Cartilage Repair Device
    9. ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
    10. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
    11. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/27/2015)... , ... July 27, 2015 , ... Visual Assay was ... celebrate the top 100 most innovative technologies and services of the past year. More ... in the Software/Services category. The winners will be announced at the 2015 R&D 100 ...
    (Date:7/25/2015)... ... July 25, 2015 , ... Technology leader Anton Paar offers ... adjusts the surface temperature of the measuring prism. This is required to achieve ... and documentation are key requirements. It is likely that no refractometer manufacturers on ...
    (Date:7/24/2015)... ... ... VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency ... opportunities. , “We are very excited to be able to partner with VetStem Biopharma ... therapy is an established treatment for arthritic conditions in our pets and is also ...
    (Date:7/24/2015)... , July 24, 2015  Champions Oncology (OTC-BB: ... technology solutions and services to personalize the development and ... its financial and operational results for the fourth quarter ... Tuesday, July 28, 2015, before market open. ... the results that day at 9:00 a.m. EDT (6:00 ...
    Breaking Biology Technology:Visual Assay® Named Finalist in 53rd Annual R&D 100 Awards 2It’s T-Time for Refractometers: On-site Temperature Check Now Available 2VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 2VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 3Champions Oncology to Announce Fourth Quarter Financial Results on Tuesday, July 28 2
    ... TKB1 competent cells , David L. ... Molecular Biology and Biotechnology, McMaster University,Ontario, Canada ... are used to affinity purify,cellular proteins, which ... ErbB2/Neu receptor tyrosine kinase (RTK). This approach ...
    ... up to 20-fold with Primary ENHANCER ,reagent ... LLC , Peter Pingerelli ,Stratagene , Stratagenes Primary ... human dermal fibroblasts. Twenty minutes,before transfection, cells are ... incubation, lipid or calcium phosphate (CaPO 4 )-mediated,transfection ...
    ... PCR product yield and specificity for difficult amplifications ... with,Perfect Match PCR Enhancer , Frances ... amplification systems produce multiple product bands or,products of ... template secondary,structures, or suboptimal PCR conditions. Stratagenes Perfect ...
    Cached Biology Technology:TKB1 Cells Identify Receptor Tyrosine Kinase Interacting Proteins 2TKB1 Cells Identify Receptor Tyrosine Kinase Interacting Proteins 3TKB1 Cells Identify Receptor Tyrosine Kinase Interacting Proteins 4TKB1 Cells Identify Receptor Tyrosine Kinase Interacting Proteins 5Improve Lipid- or Calcium Phosphate-Mediated Transfection of Human Dermal,Fibroblasts 2Improve Lipid- or Calcium Phosphate-Mediated Transfection of Human Dermal,Fibroblasts 3Optimizing pfuturbo DNA Polymerase Amplification Reactions with,Perfect Match PCR Enhancer 2Optimizing pfuturbo DNA Polymerase Amplification Reactions with,Perfect Match PCR Enhancer 3Optimizing pfuturbo DNA Polymerase Amplification Reactions with,Perfect Match PCR Enhancer 4Optimizing pfuturbo DNA Polymerase Amplification Reactions with,Perfect Match PCR Enhancer 5Optimizing pfuturbo DNA Polymerase Amplification Reactions with,Perfect Match PCR Enhancer 6
    (Date:7/9/2015)... 2015  Unchained Labs just can,t get enough ... Avid Nano. Avid Nano designs, develops and manufactures ... Also today, Unchained Labs UNcaged the ... use protein sizing system. The pUNk is a ... size, size distribution, aggregation population and molecular weight. ...
    (Date:7/8/2015)... YORK , July 8, 2015 Summary ... globally, and the fourth most fatal, with a mortality ... The poor prognosis of pancreatic cancer patients has highlighted ... treatment, which is not being met by the current ... an array of products with varying molecule types and ...
    (Date:7/8/2015)...  Trovagene, Inc. (NASDAQ: TROV ), a ... launch of a study that aims to determine ... technology for predicting response to treatment in advanced ... the novel immunotherapy agents Yervoy® (ipilumumab), a CTLA-4 ... 50-patient study will be led by researchers at ...
    Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
    ... Plumes of harmful air pollutants can be transported across oceans ... from the United States to Europe -- and have a ... says a new report by the National Research Council. ... emissions, the influence of non-domestic pollution sources may grow as ...
    ... babies breathe to techniques for imaging live neurons and beating ... being deployed in medicine and the biosciences will be on ... Optics (FiO), which takes place Oct. 11-15 at the Fairmont ... Jose, Calif. Information on free registration for reporters is ...
    ... an animal. By manipulating the DNA of mice, flies, frogs ... genes and molecules behind many of life,s essential processes. These ... they do in "model" animals. But if you want to ... learn language from one another, you need a more sophisticated ...
    Cached Biology News:Air pollutants from abroad a growing concern, says new report 2Air pollutants from abroad a growing concern, says new report 3Bio-optics breakthroughs: Highlights of medical and bioscience research at Frontiers in Optics 2009 2Bio-optics breakthroughs: Highlights of medical and bioscience research at Frontiers in Optics 2009 3Bio-optics breakthroughs: Highlights of medical and bioscience research at Frontiers in Optics 2009 4Bio-optics breakthroughs: Highlights of medical and bioscience research at Frontiers in Optics 2009 5Bio-optics breakthroughs: Highlights of medical and bioscience research at Frontiers in Optics 2009 6Bio-optics breakthroughs: Highlights of medical and bioscience research at Frontiers in Optics 2009 7Transgenic songbirds provide new tool to understand the brain 2
    Assay Diluent 500 mls...
    Protein Marker Detection Pack contains biotinylate...
    This antibody is specific for human J-chain as defined by ELISA assay using purified human immunoglobulin fragments as solid phase target antigen....
    UltraMount is formulated for coverslipping sections stained with alcohol soluble chromogens, such as Fast-Red or AEC. No heating is required prior to use. Coverslips may be removed by soaking in wate...
    Biology Products: